Dendreon announced today that it has won FDA approval for its second factory in Los Angeles for the production of sipuleucel-T (Provenge), its treatment for prostate cancer. This complements its original plant in New Jersey. Dendreon is alos seeking FDA approval on a third plant in Atlanta that it hopes to bring on line by late August.
The new capacity is good news for Dendreon which struggled most of last year and this in keeping up with Provenge demand. The added capacity is essential for Dendreon to meet its 2011 sales forecast of $350 to $400 million. See Xconomy.
Posted by Bruce Lehr June 30th 2011.